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590Background: The St Jude Medical Inc (St Paul, Minn) Trifecta valve is a novel aortic biological prosthesis that
incorporates several design features, including a true supra-annular sewing cuff, a stent design that maximizes
valve hemodynamics while minimizing leaflet stresses, and an ethanol-based anticalcification technology. This
study establishes the safety and early clinical and hemodynamic performance of the Trifecta valve.
Methods: The Trifecta bioprosthesis was implanted in 1014 eligible patients between 2007 and 2009 at 31 cen-
ters. The mean age of the population was 72.5  9.0 years, of whom 650 (64.1%) were male and 364 (35.9%)
were female. Eighty-two subjects (8.1%) had undergone previous open surgery. Indications for aortic valve re-
placement surgery included stenosis in 556 patients (54.8%), regurgitation in 61 patients (6.0%), and mixed
pathology in 397 patients (39.2%).
Results: The overall follow-up included 844.3 late patient-years. Early (30 day) mortality occurred in 18 pa-
tients (1.8%), and there were 23 late (31 days) deaths yielding a linearized mortality rate of 2.72% per late
patient-year. There were 27 early thromboembolic events, including 8 (0.8%) strokes, 17 (1.7%) reversible neu-
rologic events, and 2 (0.2%) systemic embolic events. There were no instances of early valve thrombosis,
endocarditis, or clinically significant hemolysis. There were 16 late thromboembolic events (linearized rate
of 1.90% per year of follow-up), including 4 strokes and 12 reversible neurologic events. In total, there were
5 late valve explants, including 1 structural deterioration and 4 prosthetic valve endocarditis cases. Overall, free-
dom from valve explant was 99.4% at 2 years. At the time of discharge, average mean gradients ranged from 9.3
to 4.1 mm Hg and effective orifice area ranged from 1.58 to 2.50 cm2 for valve sizes 19 to 29 mm, respectively.
Conclusions: The St Jude Medical Trifecta valve is a unique pericardial bioprosthesis with design elements that
provide excellent hemodynamic performance while providing ease of implantation. Long-term follow-up
continues to confirm the promising results of this innovative bioprosthesis. (J Thorac Cardiovasc Surg
2014;147:590-7)Bioprosthetic valves are implanted in approximately 80%
of patients requiring aortic valve replacement in North
America.1 During the past 4 decades, there has been a con-
sistent, iterative improvement in bioprosthetic valve lon-
gevity and hemodynamic performance based on valve
design and tissue processing.2-5 The St Jude Medical Inc
(St Paul, Minn) Trifecta valve is a novel biological
prosthesis that incorporates several design features,
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The Journal of Thoracic and Cardiovascular Surgthat maximizes valve hemodynamics while minimizing
leaflet stresses, and an ethanol-based anticalcification
technology.
The Trifecta pericardial aortic valve was evaluated in
a rigorousmulticenterUSFood andDrugAdministration In-
vestigational Device Exemption study conducted between
2007 and 2011. Data from 31 centers in the United States,
Canada, Germany, France, Italy, TheNetherlands, and Swit-
zerland involving 1022 patients were collected to obtain reg-
ulatory approvals. This study establishes the safety and early
clinical and hemodynamic performance of the Trifecta valve
in one of the largest prospective evaluations ever performed
on any surgical aortic valve prosthesis.
MATERIALS AND METHODS
Patients
The Trifecta bioprosthesis was implanted in 1022 patients between 2007
and 2009. Eight subjects were excluded from the analysis who did not meet
the prespecified study eligibility criteria, resulting in an analysis dataset of
1014 patients. A list of participating institutions and Principal Investigators
is in Appendix Table I. Inclusion criteria necessitated a patient of legal age
requiring aortic valve replacement who could sign for informed consent
and complete the follow-up requirements of the study. Exclusion criteria
included being pregnant or nursing; requiring other concomitant valveery c February 2014
FIGURE 1. Distribution of enrolled patients by age range, N ¼ 1014.
Abbreviations and Acronyms
EOA ¼ effective orifice area
EOAI ¼ effective orifice area index
NYHA ¼ New York Heart Association
PPM ¼ patient–prosthesis mismatch
TAVR ¼ transcatheter aortic valve replacement
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Dreplacement surgery; active endocarditis; presence of other significant
cardiovascular abnormality, such as aortic dissection; acute preoperative
(within 30 days before implant) neurologic event; renal dialysis; a history
of substance abuse in the past year; inability to perform follow-up require-
ments or predicted life expectancy less than 2 years; or participating
in another Investigational Device Exemption or Investigational New
Drug study. Institutional review board approval was obtained at every
participating site.
The mean age of the population was 72.5 9.0 years. Among the 1014
study patients, 95 (9.4%) were aged less than 60 years at the time of im-
plant and 210 (20.7%) were aged 80 years or more at the time of implant
(Figure 1). There were 650 men (64.1%) and 364 women (35.9%). Eighty-
two subjects (8.1%) had undergone previous open surgery. Preoperatively,
the majority of patients had New York Heart Association (NYHA) class II
or III symptoms. NYHA class IV symptoms occurred preoperatively in 55
patients (5.4%). Indications for aortic valve replacement surgery included
stenosis in 556 patients (54.8%), regurgitation in 61 patients (6.0%), and
mixed pathology in 397 patients (39.2%). Sixteen patients (1.6%) had
a previous prosthetic aortic valve or aortic homograft explanted, whereas
the remainder of procedures were performed on the patient’s native aortic
valve. Calcific stenosis of a trileaflet valve was observed in 696 patients
(68.6%), bicuspid pathology was observed in 295 patients (29.1%), and
23 patients (2.3%) had rheumatic disease. Other aortic valve disease and
causes were observed in 53 patients (5.2%). Preoperative demographic
information is presented in Table 1.
Aortic Valve Implantation Operative Details
Valve description. The Trifecta valve is a 3-leaflet stented pericar-
dial valve designed for supra-annular placement in the aortic position.
The valve is fabricated using a polyester-covered titanium stent. The stent,
excluding the sewing cuff, is covered with porcine pericardial tissue. This
covering is designed to provide protection frommechanical wear by allow-
ing only tissue-to-tissue contact during valve opening and closing. A
silicone insert in the polyester sewing cuff is contoured to conform to the
shape of the native annulus while providing access to the coronary artery
ostia. The valve leaflets are fabricated from bovine pericardium. The
porcine and bovine pericardium are preserved and crosslinked in glutaral-
dehyde. Glutaraldehyde, formaldehyde, and ethanol are used in the valve-
sterilization process. The Trifecta valve is processed with ethanol-based
Linx anticalcification technology.6 Valve sizes are available in 2-mm incre-
ments from 19 to 29 mm. The nominal valve size is based on the outer
diameter of the stent. Implanted sizes are outlined in Figure 2. The valve
is designed to be implanted in the true supra-annular position, typically
with noneverting pledgeted mattress sutures placed on the ventricular
side of the aortic annulus.
Among 1014 implanted valves, 56 were placed with simple interrupted
sutures, 34 were placed with nonpledgetedmattress sutures, 57 were placed
using a continuous running technique, 56 were placed using an intra-
annular technique with everting pledgeted mattress sutures placed on the
aortic side, and 811 were placed using the recommended supra-annular
technique. Concomitant procedures included coronary artery bypass graft-
ing in 372 patients (36.7%), mitral valve repair in 38 patients (3.7%),
tricuspid valve repair in 23 patients (2.3%), Maze or other cardiac ablationThe Journal of Thoracic and Caprocedures in 66 patients (6.5%), and atrial septal defect repairs in 38 pa-
tients (3.7%). Aortic root enlargement was performed in 17 patients
(1.7%). An intra-aortic balloon pump was placed at the time of surgery
in 17 patients (1.7%). The mean aortic crossclamp time for isolated aortic
valve replacement with the Trifecta valve was 64.3  25.5 minutes. Oper-
ative information is presented in Table 2.
End point definitions. Adverse events were classified according to
the standardized definitions from the Society of Thoracic Surgeons/
American Association for Thoracic Surgery ‘‘Guidelines for Reporting
Morbidity and Mortality and Cardiac Valvular Operations’’ and the
requirements of the US Food and Drug Administration.7 Events were clas-
sified as occurring early (within 30 days of implant) or late (31 days
after implant).
Data Analysis
Statistical analyses were performed using SAS software (v 9; SAS insti-
tute Inc, Cary, NC). Descriptive data are presented as mean values with
standard deviation for continuous variables and as counts with percentages
for categoric variables. Statistical significance was determined using
a 2-sample t test or Fisher exact test as appropriate. Late adverse event rates
(ie, those occurring31 days postimplant) were determined using both lin-
earized rates and Kaplan–Meier analyses.
Patient Follow-up
The overall late follow-up included 844.3 patient-years with a median
follow-up interval of 0.90 years (standard deviation, 0.45 years; interquar-
tile range, 0.50-0.99 years). The completeness of follow-up at 1 and 2 years
was 97.7% and 98.0% of patients, respectively. Echocardiographic evalu-
ation was completed at discharge, 6 months, and 1 year in 98.4%, 96.9%,
and 94.5% of patients, respectively. The follow-up was performed at the
local investigating sites by clinic evaluation at 6 months, 1 year, and annu-
ally thereafter. Study visits included clinical determination of NYHA func-
tional classification, study echocardiograms, blood assessment including
plasma free hemoglobin, medication review including anticoagulants,
and documentation of any adverse events. Study echocardiograms and
blood laboratory assessments were evaluated at central core laboratories.rdiovascular Surgery c Volume 147, Number 2 591
TABLE 1. Patient demographics
Variable All implants (N ¼ 1014)
Age at implant (y) 72.5  9.0 (32-95)
Subject gender (male) 64.1% (650)
Medical history
Hypertension 81.9% (830)
Low ejection fraction (<50%) 12.4% (126)
Hyperlipidemia 71.2% (722)
Coronary artery disease 58.2% (590)
Smoking history (previous or current) 55.7% (565)
Diabetes 24.8% (251)
Carotid artery disease 21.3% (216)
Pulmonary hypertension 17.3% (175)
Myocardial infarction 12.9% (131)
Peripheral vascular disease 10.9% (111)
Kidney disease 7.0% (71)
Stroke, cerebrovascular accident,
reversible ischemic neurologic deficit
6.0% (61)
Transient ischemic attack 7.3% (74)
Preoperative NYHA
Class I 6.6% (67)
Class II 44.1% (447)
Class III 43.9% (445)
Class IV 5.4% (55)
Predominant preoperative cardiac rhythm
Sinus 88.3% (895)
Atrial fibrillation/flutter 8.8% (89)
Paced 2.7% (27)
Other 0.3% (3)
Previous cardiovascular surgery/procedure
None 72.4% (734)
Aortic valve repair 0.3% (3)
Aortic valve replacement 1.5% (15)
Mitral valve repair 0.1% (1)
Mitral valve replacement 0.0% (0)
CABG 6.5% (66)
Percutaneous coronary intervention 14.3% (145)
Balloon valvuloplasty 1.1% (11)
NYHA, New York Heart Association; CABG, coronary artery bypass grafting.
FIGURE 2. Distribution of valves sizes implanted, N ¼ 1014.
TABLE 2. Operative details
Variable
No. of patients
(N ¼ 1014) Mean ± SD (min)
Aortic crossclamp time
All subjects 1014 83.2  37.3
With concomitant procedure 586 96.9  38.5
Without concomitant procedure 428 64.3  25.5
Cardiopulmonary bypass time
All subjects 1014 111.5  51.0
With concomitant procedure 586 129.7  52.8
Without concomitant procedure 428 86.6  35.8
No. of patients
(N ¼ 1014) %
Concomitant procedures
CABG 372 36.7
Mitral valve repair 38 3.7
Tricuspid valve repair 23 2.3
Maze 42 4.1
Cardiac ablation 29 2.9
Maze or cardiac ablation 66 6.5
ASD 38 3.7
Root enlargement 17 1.7
SD,Standard deviation;CABG,coronary artery bypass grafting;ASD, atrial septal defect.
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DRESULTS
Clinical Events
Early (30 days postimplant) mortality occurred in 18
patients (1.8%). There were 27 early thromboembolic
events, including 8 (0.8%) strokes, 17 (1.7%) reversible
neurologic events, and 2 (0.2%) systemic embolic events.
Of the 27 early thromboembolic events, 8 were known to
be in atrial fibrillation. There were 81 (8.0%) instances of
major bleeding, of which 61 (6.0%) were procedure-
related. There was 1 early valve explant due to suture injury
to a congenitally malpositioned intramural coronary artery.
The bioprosthetic valve was functioning normally at the
time of explant. The coronary artery was not obstructed
by the prosthesis. There were no instances of early struc-
tural deterioration, valve thrombosis, endocarditis, or clini-
cally significant hemolysis. Early clinical events are
presented in Table 3.592 The Journal of Thoracic and Cardiovascular SurgLate Clinical Events
Late clinical events are those events that occurred 31 days
or more postimplant. There were 23 deaths, yielding a linear-
ized mortality rate of 2.72% per late patient-year. Of these, 3
(0.36%per late patient-year)werevalve related and4 (0.47%
per late patient-year) were cardiac related. Overall Kaplan–
Meier survival was 95.8% at 1 year and 94.5% at 2 years.
Freedom from valve-related mortality was 99.4% at 2 years.
There were 16 thromboembolic events (linearized rate of
1.90% per late patient-year of follow-up), including 4
strokes and 12 reversible neurologic events. Of these
patients, 1 was known to be in atrial fibrillation. Overall
freedom from thromboembolic events was 92.9% at 2
years. There were 22 instances of major bleeding (linear-
ized rate of 2.61% per late patient-year). Freedom from
major bleeding events was 86.0% at 2 years. There was 1ery c February 2014
TABLE 3. Early adverse event rates
Safety measures for the early
postoperative period
No. of early
events*
N ¼ 1014
Early ratey
% (95%
upper CL)
Thromboembolism 27 2.7 (3.7)
Neurologic 25 2.5 (3.4)
Transient ischemic attack 3 0.3 (0.8)
Reversible ischemic neurologic deficit 14 1.4 (2.2)
Stroke 8 0.8 (1.4)
Systemic 2 0.2 (0.6)
Valve thrombosis 0 0.0 (0.3)
Major bleed 81 8.0 (9.5)
Procedure related 61 6.0 (7.4)
Anticoagulant or antiplatelet related 14 1.4 (2.2)
Anticoagulant with or without
antiplatelet
9 0.9 (1.5)
Other bleed 6 0.6 (1.2)
Nonstructural dysfunction 3 0.3 (0.8)
Paravalvular leak 1 0.1 (0.5)
Minor paravalvular leak 1 0.1 (0.5)
Major paravalvular leak 0 0.0 (0.3)
Endocarditis 0 0.0 (0.3)
Clinically significant hemolysis 0 0.0 (0.3)
Structural deterioration 0 0.0 (0.3)
Reoperation 1 0.1 (0.5)
Repair 0 0.0 (0.3)
Explant 1 0.1 (0.5)
Mortality 18 1.8 (2.6)
Valve-related 2 0.2 (0.6)
CL,Confidence limit. *Early events are those occurring on or before 30 days post-im-
plant. yEarly rate is calculated as number of early events*100/number of subjects.
TABLE 4. Late adverse event rates
Safety measures for the
latepostoperative period
(31 d postimplant)
No. of
late
events
Late rate*
(late patient-y ¼ 844.3)
%/late patient-y
(95% upper CL)
Thromboembolism 16 1.90 (2.88)
Neurologic 16 1.90 (2.88)
Transient ischemic attack 11 1.30 (2.16)
Reversible ischemic neurologic
deficit
1 0.12 (0.56)
Stroke 4 0.47 (1.08)
Systemic 0 0.00 (0.35)
Valve thrombosis 0 0.00 (0.35)
Major bleed 22 2.61 (3.72)
Anticoagulant or antiplatelet
related
16 1.90 (2.88)
Anticoagulant with or without
antiplatelet
7 0.83 (1.56)
Other bleed 6 0.71 (1.40)
Nonstructural dysfunction 1 0.12 (0.56)
Paravalvular leak 0 0.00 (0.35)
Minor paravalvular leak 0 0.00 (0.35)
Major paravalvular leak 0 0.00 (0.35)
Endocarditis 9 1.07 (1.86)
Clinically significant hemolysis 0 0.00 (0.35)
Structural deterioration 1 0.12 (0.56)
Reoperation 5 0.59 (1.25)
Repair 0 0.00 (0.35)
Explant 5 0.59 (1.25)
Mortality 23 2.72 (3.86)
Valve-related 3 0.36 (0.92)
CL, Confidence limit. *More than 31-day adverse event rate (%) is calculated as the
number of events divided by the total patient-years times 100.
FIGURE 3. All-cause mortality.
Bavaria et al Acquired Cardiovascular Disease
A
C
Dinstance of nonstructural dysfunction that did not require
explantation. Endocarditis occurred in 9 patients (linearized
rate of 1.07% per late patient-year). Freedom from pros-
thetic valve endocarditis was 98.6% at 2 years. There was
1 instance of structural valve deterioration requiring explan-
tation. There was no overt calcification of the valve cusps.
In total, there were 5 valve explants, including 1 case of
structural deterioration and 4 cases of prosthetic valve endo-
carditis. Overall, freedom from valve explant was 99.4% at
2 years. There were no instances of valve thrombosis or
clinically significant hemolysis. Late clinical event rates
are summarized in Table 4 and Figures 3 to 6.
New York Heart Association Results
At 2 years of clinical follow-up, 83.5% of patients had
NYHA class I functional status. A further 14.4% of patients
had NYHA class II status, and 2.1% of patients had NYHA
class III status. There were no instances of NYHA func-
tional class IV status in follow-up. At 2 years, freedom
from NYHA class III or IV symptoms was 96.1%.
Hemodynamic Results
Hemodynamic results at discharge and 1 year for each
valve size are presented in Figures 7 to 10. At the time ofThe Journal of Thoracic and Cadischarge, average mean gradients ranged from 9.3 to 4.1
mm Hg and average peak gradients ranged from 17.8 to
7.8 mm Hg for valve sizes 19 to 29 mm, respectively. At
1 year of follow-up, average mean gradients ranged from
10.7 to 4.7 mm Hg and average peak gradients ranged
from 19.9 to 9.2 mmHg for valve sizes 19 to 29mm, respec-
tively. Average effective orifice area (EOA) ranged fromrdiovascular Surgery c Volume 147, Number 2 593
FIGURE 4. Valve-related mortality. FIGURE 6. Freedom from NYHA III or greater. NYHA, New York Heart
Association.
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D1.58 to 2.50 cm2 at the time of discharge and from 1.41 to
2.35 cm2 at 1 year for valve sizes 19 to 29 mm, respectively.
At the time of discharge, 12 patients (1.2%) had mild
aortic insufficiency, and 4 patients (0.4%) had moderate
aortic insufficiency. There were no early cases of severe in-
sufficiency. At 1 year, 11 patients (1.8%) had mild aortic
insufficiency, 6 patients (1.0%) had moderate aortic insuf-
ficiency, and 3 patients (0.5%) had severe aortic insuffi-
ciency (Figure 11). At 1 year, moderate or greater aortic
insufficiency was observed in 9 patients (1.5%). Paravalv-
ular leaks were exceedingly uncommon with only 1
(0.1%) minor paravalvular leak observed in the early period
(Figure 12).
Mild to moderate patient–prosthesis mismatch (PPM) as
defined by an effective orifice area index (EOAI) of 0.65 to
0.85 cm2/m2 occurred in 209 patients (22.8%) at the time of
discharge. Severe PPM, defined as an EOAI less than 0.65
cm2/m2, was found in 18 patients (2.0%) at the time of dis-
charge and 32 patients (5.5%) at 1 year. Overall freedom
from severe PPM at 1 year was 94.8%. Mean indexed left
ventricular mass for subjects who had values at all 3 postop-
erative time points decreased from 115.4 g/m2 at the time of
discharge to 107.0 g/m2 at 6 months, 105.1 g/m2 at 1 year,FIGURE 5. Freedom from Trifecta (St Jude Medical Inc, St Paul, Minn)
valve explant.
594 The Journal of Thoracic and Cardiovascular Surgand 100.2 g/m2 at 2 years (P<.001 for all time points vs left
ventricular mass at discharge) (Figure 13).DISCUSSION
Characteristics of the ideal aortic prosthesis include ease
of implant, lack of intrinsic thrombogenicity that does not
require therapeutic anticoagulation, no residual transvalvu-
lar pressure gradient, a physiologic orifice area that can
adapt to exercise conditions, and long-term durability.6,8,9
The Trifecta valve prosthesis was designed to specifically
address some of the fundamental limitations of previous
aortic valve bioprostheses. Specifically, it was designed
with a concave, slightly scalloped sewing ring to conform
to the aortic annulus and provide adequate clearance for
the native coronary arteries. Attachment of the
bioengineered single sheet of bovine pericardium around
the external aspects of the titanium stent allows for
maximal cylindrical opening during systole. In addition,
the titanium stent has intrinsic distensibility, potentially
allowing for further expansion of the prosthesis in high-
load conditions such as exercise.
The purpose of the current investigation was to establish
the safety and hemodynamic profile of the Trifecta aortic
valve prosthesis. One important trend observed in the cur-
rent study and other recent multicenter evaluations ofFIGURE 7. Average mean valve gradients over time.
ery c February 2014
FIGURE 8. Average peak valve gradients over time. FIGURE 10. Average EOAI. EOAI, Effective orifice area index.
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Dbiologic valve prostheses is that the average age of the pa-
tients was fairly high at 72.5 years.6,10,11 Despite the
advanced age and higher risk profile, the clinical results
of the patients in this study were exemplary. Perioperative
mortality was 1.8%, and overall survival was 94.5% at 2
years. This compares favorably to contemporary
multicenter valve performance studies in similar patient
populations by Conte and colleagues10 evaluating the Sorin
Mitroflow (Sorin Group, Milan, Italy) pericardial aortic
prosthesis, Fradet and colleagues11 evaluating the Med-
tronic Mosaic (Medtronic Inc, Minneapolis, Minn) porcine
aortic prosthesis, and Jamieson and colleagues6 evaluating
the St Jude Epic (St Jude Medical Inc) porcine prosthesis.
On the basis of the results of the current study, the Tri-
fecta valve represents significant progress in the develop-
ment of a stented bioprosthesis with near physiologic
hemodynamics. The nearly cylindric opening of the pros-
thesis on systole provides gradients and EOAs that surpass
any other available stented aortic prosthesis and approach
those of stentless prostheses.6,10-12,14,15
Although study-to-study comparisons of different aortic
prostheses are confounded by many factors, among multi-
center studies with rigorous centralized core laboratory anal-
ysis echocardiographic follow-up, the Trifecta valve showed
favorable hemodynamics to other pericardial prostheses.10,12
At 1 year, EOAs for the Trifecta valve, Sorin Mitroflow,10
Medtronic Mosaic,11 and Edwards Magna Ease12 (Edwards
Lifesciences, Irvine, Calif) were 1.4, 1.1, 1.2, and 1.3 cm2
for the 19-mm prosthesis; 1.6, 1.2, 1.3, and 1.5 cm2 for theFIGURE 9. Average EOA. EOA, Effective orifice area.
The Journal of Thoracic and Ca21-mm prosthesis; and 1.8, 1.4, 1.5, and 1.8 cm2 for the
23-mm prosthesis, respectively. In a nominal size-by-size
comparison, the 6-month EOAs for the Trifecta valve versus
the St JudeMedical Toronto stentless porcine valve (full root
implants only) were 1.7 and 1.2 cm2 for the 21-mm prosthe-
ses, 1.9 and 1.5 cm2 for the 23-mm prostheses, 2.1 and 1.9
cm2 for the 25-mm prostheses, 2.2 and 2.3 cm2 for the
27-mm prostheses, and 2.5 and 2.6 cm2 for the 29-mm pros-
theses, respectively.13 The presence of a titanium stent that
may be able to expand during high loading conditions,
such as exercise, may provide additional clinical benefit
and minimize leaflet stresses as seen in stentless porcine
valves. In addition, optimal leaflet shaping and coaptation
are achieved through a proprietary leaflet fixation method.
The favorable hemodynamics led to an incidence of
severe PPM that was uniquely low for the Trifecta valve.
Among patients receiving 19-, 21-, and 23-mm prostheses,
at 1 year, the mean EOAI was 0.85, 0.90, and 0.91 cm2/m2,
respectively. Severe mismatch with an EOA less than 0.65
cm2/m2 was found in only 2.0% of patients at the time of
discharge. The presence of severe PPM has been shown in
several studies to lead to significantly poorer long-term sur-
vival in a variety of patient groups. In series with older-
generation prostheses and varying definitions of mismatch,
its incidence has been reported up to 51%.15,16
The discussion of near physiologic hemodynamics seen
in the Trifecta valve is particularly important with theFIGURE 11. Total aortic insufficiency over time.
rdiovascular Surgery c Volume 147, Number 2 595
FIGURE 12. Paravalvular leak over time.
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(TAVR) technologies.17-19 TAVR valves have been
purported in several nonrandomized studies to have
hemodynamics superior to open surgical valves, with low
residual gradients due to the nonobstructive nature of the
metallic stent and lack of sewing ring.19 In the only large
multicenter randomized controlled trial comparing TAVR
with open aortic valve replacement in high-risk patients,
the difference in postoperative gradients was in the low sin-
gle digits and not likely to be clinically significant.20
Although TAVR valves tend to be hemodynamically effi-
cient in systole, paravalvular leaks, and to a lesser extent in-
travalvular leaks, seen frequently in the first-generation
devices represent true sources of energy loss that may limit
the full clinical benefit of the relief of severe aortic stenosis.
A recent bench study by Azadani and colleagues21 revealed
that energy loss in the setting of even mild aortic regurgita-
tion from a paravalvular leak may be as hemodynamically
important as a modest residual gradient. Aortic regurgita-
tion, predominantly from paravalvular sources, is present
in more than 51% of TAVR valves, and moderate or worse
regurgitation is generally described in up to 13% of TAVR
valves.17,18,22,23 In the current study, the Trifecta valve had
a low rate of paravalvular leak (Figure 12) despite having
a highly efficient low-profile sewing ring, indicative of
ease of implantability. There was also minimal valvularFIGURE 13. Left ventricular mass regression.
596 The Journal of Thoracic and Cardiovascular Surgregurgitation even in larger sizes, a problem more common
in previous-generation surgical pericardial valves.24CONCLUSIONS
The St Jude Medical Inc Trifecta valve is a unique peri-
cardial bioprosthesis with design elements that incorporate
significant improvements in hemodynamic performance
over previous-generation valves while providing ease of im-
plantation. Long-term follow-up continues to confirm the
promising results of this innovative bioprosthesis.References
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